Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
New Post
Russian hacker sentenced to 9 years in prison for role in insider trading scheme
September 13, 2023
News Alert
Two defendants plead guilty for their roles in an insider trading scheme
September 8, 2023
News Alert
Visiting attorney from Brazil charged in the US with insider trading
August 28, 2023
News Alert